Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age

Authors

Institutions

Publication Details

Journal
Expert Opinion on Drug Safety
Published
2025-06-13
DOI
https://doi.org/10.1080/14740338.2025.2519835
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age

Yusuke Naito, Sakurako Watanabe, Kazuhiro Yamamoto
Expert Opinion on Drug Safety
Diabetes Treatment and Management
article

Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age

Yusuke Naito, Sakurako Watanabe, Kazuhiro Yamamoto
article en

Abstract

No abstract available for this paper.
Expert Opinion on Drug Safety
National Cerebral and Cardiovascular Center (JP), Boehringer Ingelheim (Japan) (JP), Boehringer Ingelheim (Philippines) (PH)
Openalex Percentile: Top 81%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.